Peptides 101

Peptides are short chains of amino acids joined by peptide bonds. Chain length is the everyday dividing line people use between peptides and proteins, and the boundary is a convention rather than a hard rule.

• Amino acids are the building blocks; a peptide bond is the covalent link formed between them.
• Sequence (the order of amino acids) is what distinguishes one peptide from another.
• Short chains are usually called peptides; longer chains are usually called proteins. There is no single agreed cut-off.
• Marketing takeaway: describe a material by its identity and its research-use classification, never by what it supposedly does for a person.

Many peptides are studied because biological systems use signalling molecules that interact with receptors. This is background context for why laboratories study peptides at all.

• Signalling molecules bind receptors; binding can change activity inside a cell.
• Specificity, affinity, and downstream pathway are the sorts of questions laboratory research asks.
• A mechanism being investigated is not the same as an established human outcome.
• Marketing takeaway: you may describe what is being investigated in research settings. You may not translate a mechanism into a promised result for a person.

This lesson is context for research literacy. It is not guidance about use in humans or animals.

Endogenous peptides occur naturally in an organism. Synthetic peptides are manufactured, commonly by solid-phase peptide synthesis, and may be identical to, or deliberately different from, a naturally occurring sequence.

• 'Naturally occurring' says nothing about safety, legality, or approval status.
• Analogues are modified sequences studied for changed stability or binding characteristics.
• Synthesis route, identity, and purity are supplier-documented facts, not marketing claims.

A working vocabulary so you read supplier documentation and literature accurately rather than guessing.

• In vitro (in cells or a test system), in vivo (in a living organism), ex vivo, preclinical, clinical.
• Analogue, agonist, antagonist, receptor, half-life, lyophilised, lot/batch.
• Identity, purity, potency — three separate ideas that are often wrongly used interchangeably.
• RUO: research use only. A classification of the material's permitted purpose, not a disclaimer that cancels out other claims.

Not all evidence carries the same weight. Knowing the ladder keeps your language honest and keeps you out of claim territory.

• Mechanistic and cell-based work sits lowest for predicting outcomes in people.
• Animal studies come next; species differences are substantial.
• Human trials are ranked by design, size, blinding, and replication; systematic reviews sit at the top.
• Marketing takeaway: Peptide King partners cite the evidence level, never leap from a cell study to a human benefit statement.

FDA-approved drugs, compounded drugs, investigational substances, and research-use-only materials are legally distinct. Mixing them up is one of the fastest routes to a regulator's attention.

• FDA-approved drug: reviewed and authorised for specific labelled uses, with an approved label.
• Compounded drug: prepared for a patient under specific conditions; not FDA-approved as a product.
• Investigational substance: under study in an authorised clinical investigation, not approved for general use.
• Research-use-only material: supplied for laboratory research; not for human or veterinary use and not for diagnostic use. A research-use label does not by itself establish legal status or override intended-use claims.
• Marketing takeaway: never describe a research-use-only material with language borrowed from any of the other three categories.

General regulatory education. This is not legal advice; partners should obtain their own counsel where their situation requires it.